| P/E TTM | 73.65Sector: 50.47 |
|---|---|
| Market Cap | ₹319.41 CrHealthcare Supplies |
| RSI | 37.31Zone: Neutral |
| Promoter Holding | 70.68%Up 2.59% QoQ |
| Metric | Q2-27 | Q1-27 | Q2-26 |
|---|---|---|---|
| Revenue from Operations | 58.5 | 40.3 | 37.7 |
| Other Income | 1.4 | 1.8 | 2.3 |
| Total Income | 59.9 | 42.2 | 40.1 |
| Profit Before Tax | 5.5 | 4.4 | 4.6 |
| Net Profit | 4.1 | 3.1 | 3.6 |
| Operating Margin | 9.2% | 10.4% | 11.5% |
| Net Profit QoQ | +32.3% | ||
| Net Profit YoY | +13.9% | ||
| Adj. Profit QoQ | +57.7% | ||
| Adj. Profit YoY | +78.3% | ||
Key highlights
- Revenue from operations reached ₹58.5 crore, up from ₹37.7 crore in the same quarter last year
- Consolidated net profit climbed 32.3% on a sequential basis to ₹4.1 crore
- Operating margins moderated to 9.2% from 11.5% YoY due to higher procurement costs
- Total income for the quarter stood at ₹59.9 crore, inclusive of ₹1.4 crore in other income
- Promoter holding increased by 2.59% during the quarter to reach 70.68%
Top-Line Growth Counters Margin Pressure
Nureca Ltd demonstrated strong top-line momentum in the second quarter of the 2026-27 fiscal year, with consolidated revenue from operations rising to ₹58.5 crore from ₹37.7 crore in the corresponding quarter last year. This 55% year-on-year growth reflects sustained demand for home healthcare and wellness products. However, the operating margin contracted to 9.2% from 11.5% in the year-ago period, primarily due to a sharp increase in the purchase of stock-in-trade, which rose to ₹52.17 crore.
Despite these cost pressures, the company maintained profitability with a net profit of ₹4.1 crore.
Strategic Merger and Manufacturing Expansion
- A scheme of merger is pending to absorb wholly-owned subsidiary Nureca Technologies Private Limited
- The merger remains subject to final sanction from the National Company Law Tribunal
- Formal approval secured from Invest Punjab to establish a manufacturing plant in Sundra
- The new facility will focus on health and wellness equipment to enhance domestic production
- Transition toward domestic manufacturing aims to reduce reliance on outsourced stock-in-trade
Operational Segment Disclosure
The Group operates in single business segment i.e. 'Home healthcare and wellness products' hence there are no reportable segments as per Ind AS 108 Operating Segments.
Comparative Performance and Market Context
On a sequential basis, Nureca's performance showed recovery with a 45% jump in revenue compared to the ₹40.3 crore recorded in Q1 FY27. Adjusted profit grew by 57.7% quarter-on-quarter, indicating improved operational efficiency in the current cycle. The company continues to operate a B2C-centric model without a fixed order book, focusing on domestic manufacturing and omnichannel growth.
With a price-to-earnings ratio of 73.65 compared to the sector average of 50.47, the market is pricing in expectations for its transition from a pure-play trading model to an integrated manufacturing entity.
| Date | Announcement | Amount |
|---|---|---|
| 21 Jul 2026 | Q1 FY27 unaudited consolidated net profitSource: hdfcsec.com | ₹3.07 Cr |
| 29 May 2026 | Q4 FY26 audited consolidated net lossSource: hdfcsec.com | ₹-6.09 Cr |
| 17 Jan 2026 | Q3 FY26 unaudited consolidated net profitSource: equitybulls.com | ₹3.73 Cr |
| 16 Oct 2025 | Q2 FY26 unaudited consolidated net profitSource: equitybulls.com | ₹3.63 Cr |
| 15 Jul 2025 | Q1 FY26 unaudited consolidated net profitSource: hdfcsec.com | ₹0.81 Cr |
| 05 May 2025 | Q4 FY25 audited financial resultsSource: nureca.com | – |
What to watch next
- NCLT sanction for the merger of Nureca Technologies Private Limited, pending as of Oct 2026
- Commissioning timeline for the Sundra, Punjab manufacturing facility in FY27
- Impact of increased promoter holding on future liquidity and market momentum
- Domestic manufacturing shift influence on operating margins in H2 FY27
“The Scheme of Merger is effective from a proposed appointed date of April 1, 2025, subject to the sanction of the National Company Law Tribunal and other regulatory approvals.”
| Share price | ₹319.4 |
|---|---|
| Market capitalisation | ₹319.41 Cr |
| Revenue (annual) | ₹146.96 Cr |
| Net profit (annual) | ₹2.08 Cr |
| Revenue (latest quarter) | ₹40.34 Cr+13.95% vs previous quarter |
| Net profit (latest quarter) | ₹3.07 Cr+150.34% vs previous quarter |
| P/E (TTM) | 73.65×Sector 50.47× |
| Promoter holding | 70.68%+2.59% QoQ |
| FII holding | 0.22%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Financial results filing by Nureca Ltd for the quarter and half-year ended September 30, 2026. Market figures from a third-party data provider.
Track Nureca live
Get the next Nureca filing on Telegram seconds after it lands. 15 days free.
